Vaxcyte (PCVX) officer plans stock sale after RSU vest
Vaxcyte officer James Wassil filed a Form 144 to sell 1,334 shares worth $80,026.66, following an RSU vest on September 7, 2026. Recent sales include 9,308 shares over three months, all executed through a broker.
How this was made
The 30-second read
Why it matters
The filing provides transparency but the $80k sale is trivial for a Nasdaq‑listed biotech.
Market read
Limited relevance; primarily a compliance disclosure with minimal market impact.
What to watch
Potential upcoming clinical trial news could make any insider activity more significant.
Background
Form 144 filings disclose planned sales of restricted securities under Rule 144, often after RSU vesting events.
Ticker impact
Officer James Wassil filed a Form 144 to sell 1,334 shares worth $80,026 after an RSU vest on Sep 7, 2026.
No material price movement expected.
The transaction size is small relative to market cap; insider sales of this magnitude rarely move the stock.
Market effects
None
None
None
Counterpoint
Even small insider sales can precede larger moves if insider has material non‑public information.
Key entities
- CompanyVaxcyte, Inc.
Biotech firm developing vaccines, ticker PCVX.
- OfficerJames Wassil
Company officer filing the sale.
